Later, the pharma giant confirmed the coronavirus vaccine could roll out to the public by early 2021. You have to do this.”And he tells Forbes the company doesn’t expect to turn a profit from any COVID-19 vaccine. So there's going to be space enough for vaccines.”The news of progression on a coronavirus vaccine boosted Johnson & Johnson stock by 7.5% on Monday, up to $132.46 per share on the New York Stock Exchange. How Johnson & Johnson vaccine worksStoffels also explained the way in which the Johnson & Johnson vaccine candidate works. The same J&J technique has been used to varying degrees of success by Johnson & Johnson, previously being used to treat HIV, ebola and zika.

Source: Forbes March 30, 2020 18:56 UTC